Galenica and Fresenius form new renal-focused firm

Fresenius Medical Care and Galenica are to launch a new renal-focused pharmaceutical company called Vifor-Fresenius Medical Care Renal Pharma to develop treatments for iron deficiency anaemia and bone mineral metabolism for pre-dialysis and dialysis patients.

Fresenius Medical Care and Galenica are to launch a new renal-focused pharmaceutical company called Vifor-Fresenius Medical Care Renal Pharma to develop treatments for iron deficiency anaemia and bone mineral metabolism for pre-dialysis and dialysis patients.

More from Cardiovascular

More from Therapeutic Category

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By 

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.